Literature DB >> 12849182

Ultrasound in the treatment of ischaemic stroke.

Michael Daffertshofer1, Michael Hennerici.   

Abstract

Intravenous alteplase (recombinant tissue plasminogen activator) has been shown to be beneficial within a short 3 h window after stroke. Ultrasound has a thrombolytic capacity that can be used for pure mechanical thrombolysis or improvement of enzyme-mediated thrombolysis. Mechanical thrombolysis with ultrasound needs high intensities at the clot (>2 W/cm2) that may have unwanted side-effects, whereas improvement of enzymatic thrombolysis can be done at the safer energy levels used in diagnostic ultrasound. Methods of improving enzymatic thrombolysis with ultrasound include intra-arterial delivery of thrombolytic agents with an ultrasound-emitting catheter and targeted and non-targeted non-invasive transcranial ultra sound delivery during intravenous thrombolytic infusion. Animal and clinical studies of sonothrombolysis have shown clot lysis and accelerated recanalisation of arterial occlusion has been seen in in vitro flow models, occluded peripheral and coronary arteries, and intracerebral arteries. Controlled clinical trials to test safety management and effectiveness of both strategies are in progress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849182     DOI: 10.1016/s1474-4422(03)00380-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  16 in total

1.  In vitro microscopic imaging of enhanced thrombolysis with 120-kHz ultrasound in a human clot model.

Authors:  Jason Y Cheng; George J Shaw; Christy K Holland
Journal:  Acoust Res Lett Online       Date:  2005-01

2.  Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.

Authors:  Susan D Tiukinhoy-Laing; Shaoling Huang; Melvin Klegerman; Christy K Holland; David D McPherson
Journal:  Thromb Res       Date:  2006-08-02       Impact factor: 3.944

3.  Effect of clot aging and cholesterol content on ultrasound-assisted thrombolysis.

Authors:  Yufeng Zhou; Suresh Kanna Murugappan; Vijay Kumar Sharma
Journal:  Transl Stroke Res       Date:  2014-02-03       Impact factor: 6.829

Review 4.  Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.

Authors:  Denis Vivien; Maxime Gauberti; Axel Montagne; Gilles Defer; Emmanuel Touzé
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

5.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

6.  MR-guided transcranial brain HIFU in small animal models.

Authors:  B Larrat; M Pernot; J-F Aubry; E Dervishi; R Sinkus; D Seilhean; Y Marie; A-L Boch; M Fink; M Tanter
Journal:  Phys Med Biol       Date:  2009-12-17       Impact factor: 3.609

Review 7.  Ultrasound-enhanced thrombolysis in acute ischemic stroke: potential, failures, and safety.

Authors:  Georgios Tsivgoulis; Andrei V Alexandrov
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

8.  Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke.

Authors:  Fabienne Perren; Jaouad Loulidi; Davide Poglia; Theodor Landis; Roman Sztajzel
Journal:  J Thromb Thrombolysis       Date:  2007-05-20       Impact factor: 2.300

9.  Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone.

Authors:  Bjarne Madsen Härdig; Jonas Carlson; Anders Roijer
Journal:  BMC Cardiovasc Disord       Date:  2008-08-26       Impact factor: 2.298

10.  Ultrasound enhanced thrombolysis: applications in acute cerebral ischemia.

Authors:  Georgios Tsivgoulis; Andrei V Alexandrov
Journal:  J Clin Neurol       Date:  2007-03-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.